COVID-19 and hypogonadism: secondary immune responses rule-over endocrine mechanisms

Hum Fertil (Camb). 2023 Feb;26(1):182-185. doi: 10.1080/14647273.2020.1867902. Epub 2021 Jan 13.

Abstract

Men show higher vulnerability to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection (COVID-19) and present with depleted testosterone levels. Reports pertaining to high luteinizing hormone (LH), while diminished levels of in COVID-19 patients negate the hypothalamic-pituitary-testicular (HPT) axis mediated lowering of testosterone. Although not evidenced, high testicular expression of angiotensin-converting enzymes-2 (ACE2), that aids viral entry into cells, may suggest direct viral-testicular invasion. However, secondary inflammation and oxidative stress (OS), owing to SARS-CoV-2 infection, are more likely to impair steroidogenesis. Moreover, blockage of ACE2 aided angiotensin II into angiotensin (1-7) conversion may also affect testosterone synthesis. SARS-CoV-2, by mimicking adrenocorticotrophic (ACTH) hormones, may trigger host antibodies against the ACTH molecules to suppress host stress response. This commentary concisely presents the possible mechanisms by which SARS-CoV-2 infection may affect testosterone levels, which possibly result in compromised male reproductive health.

Keywords: COVID-19; SARS-CoV-2; inflammation; oxidative stress; testosterone.

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • COVID-19*
  • Humans
  • Hypogonadism*
  • Immunity
  • Male
  • Peptidyl-Dipeptidase A / metabolism
  • SARS-CoV-2 / metabolism
  • Testosterone

Substances

  • Angiotensin-Converting Enzyme 2
  • Peptidyl-Dipeptidase A
  • Testosterone